Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.57 |
| ▸ | PPARG | P37231 | 13/20 | 0.56 |
| ▸ | PPARD | Q03181 | 7/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4758451 | 1.00 | PPARA (0.57) | PPARAPPARGPPARDPGRADORA3 | |
| SCHEMBL4758419 | 1.00 | PPARA (0.57) | PPARAPPARGPPARDPGRADORA3 | |
| SCHEMBL4757415 | 0.93 | PPARA (0.58) | PPARAPPARGPPARD | |
| SCHEMBL4790094 | 0.93 | PPARA (0.58) | PPARAPPARGPPARD | |
| SCHEMBL5015533 | 0.88 | PPARA (0.56) | PPARAPPARGPPARD | |
| SCHEMBL5978209 | 0.88 | PPARA (0.56) | PPARAPPARGPPARD | |
| SCHEMBL6387457 | 0.88 | PPARA (0.56) | PPARAPPARGPPARD | |
| SCHEMBL11932217 | 0.88 | PPARA (0.56) | PPARAPPARGPPARD | |
| SCHEMBL4883401 | 0.88 | PPARA (0.56) | PPARAPPARGPPARD | |
| SCHEMBL6388507 | 0.87 | PPARA (0.74) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008010238-A2 | ANTIDIABETIC AZABICYCLO [3. 1. 0] HEXAN COMPOUNDS | LUPIN LIMITED (IN) | 2008-01-24 | — | — | WO | disclosed |
| US-20050096331-A1 | Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096331-A1 | Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, CETP | PPARA 140/4885PPARG 139/4885PPARD 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.